FDA should follow EMA's lead on drug rejection disclosures, researchers say

September 9, 2026 12:51 PM EDT FDA+Law FDA should fol­low EMA's lead on drug re­jec­tion dis­clo­sures, re­searchers say Zachary Brennan Senior Editor The FDA’s ma­jor shift in Sep­tem­ber 2025 to be­gin pub­lish­ing drug re­jec­tion let­ters is still an evolv­ing process. But mov­ing for­ward, the US agency should … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER